Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What To Expect If Republicans Regain Majority: More Executive Actions, Focus On Costs

Executive Summary

Lobbyists discuss what will happen with the healthcare agenda if Republicans retake the House in the mid-term elections and the prospects for passing a prescription drug pricing bill before then.

You may also be interested in...



Senate Democrats Running Out Of Time On Drug Pricing Reform

Is less ambitious drug pricing reform better than nothing? Senate Finance Committee Chair Wyden still pushing for a version of the most aggressive policy, direct government price negotiation.  

COVID Funding: White House Pleads For Emergency Extension As ‘Runway’ To Commercial Market

Biden administration warns that additional oral antivirals may not be purchased if Congress does not provide $22.5bn emergency funding for COVID response, imperiling the new Test to Treat initiative and other programs.

Insulin Copay Bill Advances In What Could Be US Senate Democrats Last Gasp For Price Reform

Though popular, the proposal to cap insulin copays is a relatively minor part of the drug pricing reform package included in the stalled Build Back Better Act. But it may represent Democrats’ best chance of passing any drug pricing-related legislation while they still hold majorities in Congress.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel